Broadview Ventures Inc’s Post

📢 @Antag Therapeutics is pleased to announce #FDA IND clearance for AT-7687, our lead molecule for the treatment of #obesity.   AT-7687 is a peptide GIP receptor antagonist, designed for once-weekly subcutaneous administration. Preclinical studies have demonstrated that AT-7687 attenuates weight gain and enhances GLP-1-mediated weight loss while also improving lipid profiles, particularly LDL, independently of weight changes.   Our phase I clinical trial will evaluate the safety, tolerability, and pharmacokinetics of AT-7687, both as a monotherapy and in combination with #semaglutide, in healthy lean and healthy obese participants.   This is a significant milestone for #AntagTherapeutics, and we look forward to updating you as we progress AT-7687 through clinical development.   Read the full press release, linked in the comments below.   #clinicalupdate #INDclearance #GIP

Join SBIA Dec. 4 for Clinical Pharmacology Considerations for Novel Therapeutic Modalities Webinar The webinar will discuss the unique considerations for oligonucleotide therapeutics and antibody-drug conjugates, including final guidances, with respect to topics such as dose selection, exposure/response analysis, organ impairment, drug interactions, QTc assessment, and immunogenicity.

📣 December 4! SBIA | Clinical Pharmacology Considerations for Novel Therapeutic Modalities Webinar The webinar will discuss the unique considerations for oligonucleotide therapeutics and antibody-drug conjugates, including final guidances, with respect to topics such as dose selection, exposure/response analysis, organ impairment, drug interactions, QTc assessment, and immunogenicity. ➡️ Have you registered yet? https://lnkd.in/d-asxqj2

📣 Next week! SBIA | Clinical Pharmacology Considerations for Novel Therapeutic Modalities Webinar The webinar will discuss the unique considerations for oligonucleotide therapeutics and antibody-drug conjugates, including final guidances, with respect to topics such as dose selection, exposure/response analysis, organ impairment, drug interactions, QTc assessment, and immunogenicity. ➡️ There's still time to register! https://lnkd.in/d9392iu2

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy. 👶 Initial Label Would Include All Patients with Cardiomyopathy Associated with Duchenne Muscular Dystrophy. Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file a Biologics License Application (BLA) based on existing cardiac and natural history data for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy. 💪 Source: https://lnkd.in/duh2wetV #dmd #bmd #hope #science #genetherapy #dmdwarrior #dmdwarriors #duchennemusculardystrophyawareness #findacure #duchennewarriors #duchennesmusculardystrophy #duchenne #duchenneawareness #duchenneheroes #musculardystrophy #Wheelchair #DisabledLife #WheelchairLife #fysioterapia #gene #dna

NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments #brain #Parkinson #Synuclein #LewyBodyDementia #dementia #research #science Published: Jun 27, 2024 ZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results from multiple in vitro studies targeting alpha-synuclein (α-synuclein), specifically the A53T mutation, that demonstrate the compounds' potential to advance the treatment of Parkinson's Disease (PD). The compounds may be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs, Inc. (Aexon Labs or AEX). https://lnkd.in/esarhBZb

2'-Fluorinated nucleoside chemistry for new drug discovery: achievements and prospects Comprehensive overview of well-established 2'-fluorinated nucleosides approved for use in the market or those in clinical stages for antiviral and antitumor therapies, highlighting the drug discovery strategies, structure activity relationship (SAR) studies, mechanisms of actions, and preclinical/clinical studies and also discuss the challenges and future directions for nucleoside-based new drug discovery. https://lnkd.in/gZeJ6w9x

Clene Nanomedicine, Inc.., a biopharmaceutical company focused on improving mitochondrial health and treating neurodegenerative diseases, will meet with the U.S. Food and Drug Administration (FDA) before the end of November 2024. The meeting will discuss the development of Clene's proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS). The FDA representatives attending the meeting will include the director of the Office on New Drugs, the director of the Office of Neuroscience, the Division of Neurology 1 review team, and key opinion leaders in ALS, biostatistics, and biomarkers. 'CNM-Au8 is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress,' the company stated. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, is focused on developing treatments for neurodegenerative diseases like ALS, Parkinson's disease, and multiple sclerosis. #neurodegenerativediseases #als #fda @cleneinc @fdanews

Cerevel Therapeutics announces positive topline results for Tavapadon in phase 3 adjunctive trial for people living with Parkinson’s disease. The TEMPO-3 trial evaluated its efficacy, safety and tolerability met the primary endpoint and key secondary endpoint. The neurotransmitter dopamine is linked to working memory and motor movement, and the loss of dopamine-producing neurons in the brain result in Parkinson’s disease. Tavapadon is a selective dopamine D1/D5 receptor partial agonist for the improved motor control. While most dopamine agonists target and stimulate D2/D3 dopamine receptors, Tavapadon is the only D1/D5 selective partial agonist in clinical development for PD. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gdhhbE9D #PD #Phase3 #motor #Dopamine #Receptors #D1 #D1R #D5 #partial #agonist